study of blood donors who later developed RA. 10 Conversely, the plasma concentrations of apolipoprotein A-I and HDL cholesterol are increased in patients who respond to treatment with disease-modifying antirheumatic drugs when compared with nonresponders. 11 When considered together, these results suggest that therapies that increase HDL levels may potentially reduce joint inflammation in RA.
We have reported that intravenous infusions of apolipoprotein A-I and reconstituted HDLs (rHDLs) consisting of apolipoprotein A-I complexed with phospholipid inhibit endothelial cell adhesion molecule expression and infiltration of neutrophils into inflamed carotid arteries in New Zealand White rabbits. 7, 12, 13 They also reduce chemokine and chemokine receptor expression in apoE-knockout mice, 14 inhibit inflammatory cytokine production in monocytes by direct contact with stimulated T lymphocytes, 15 and reduce chemokine and chemokine receptor expression in fibroblast-like synoviocytes. 16 Apolipoprotein A-I-containing rHDLs also attenuate adhesion molecule expression in tumor necrosis factor (TNF)-α-stimulated endothelial cells. 13, 17 Moreover, treatment with an apolipoprotein A-I mimetic peptide has been shown to reduce serum inflammatory cytokine levels significantly and to inhibit collagen-induced arthritis in rats. 18 These anti-inflammatory functions of HDLs are particularly relevant in the context of RA in humans, whereas proinflammatory cytokine, chemokine, adhesion molecule, and growth factor production by synovial tissues recruits inflammatory cells into joints, thus exacerbating the disease.
The present study questions whether intravenous infusions of lipid-free apolipoprotein A-I and (A-I)rHDLs inhibit streptococcal cell wall PG-polysaccharide (PG-PS)-induced arthritis in female Lewis rats, an experimental animal model of arthritis that has many features in common with human RA. 19 The results show that apolipoprotein A-I and rHDLs effectively reduce joint inflammation in this animal model by inhibiting TLR2 expression and activation. Additional studies in human monocyte-derived macrophages (HMDMs) have established that apolipoprotein A-I and rHDLs mediate these effects by decreasing NF-κB activation in an ABCA1-and ABCG1-dependent manner.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results Apolipoprotein A-I Prevents PG-PS-Induced Arthritis in Female Lewis Rats
Arthritis was induced in female Lewis rats as described in Materials and Methods in the online-only Data Supplement and Figure I in the online-only Data Supplement. Joint inflammation in the animals that received intravenous saline infusions 24 hours before and at days 1, 7, 9, and 11 after PG-PS administration progressed from an initial, acute inflammatory phase during the first 4 days after PG-PS administration to remission by day 8. These animals subsequently developed chronic joint inflammation that persisted until euthanasia at day 21 ( Figure 1A -1C, closed circles, S/S). Joint inflammation was not evident in control animals that received intravenous saline infusions 24 hours before and at days 1, 7, 9, and 11 after a single intraperitoneal saline injection ( Figure 1A , closed triangles, S/S). Administration of apolipoprotein A-I 24 hours before and 24 hours after the intraperitoneal PG-PS injection, followed by 3 intravenous saline injections on days 7, 9, and 11 after the PG-PS injection, decreased the acute and chronic phases of arthritis by 63±9% at day 3 and by 61±8% at day 21 ( Figure 1A , open circles, AI/S; P<0.05 for both). Infusion of saline 24 hours before and 24 hours after the PG-PS injection, followed by infusion of apolipoprotein A-I on days 7, 9, and 11 after the PG-PS injection, had no effect on acute joint inflammation but reduced chronic joint inflammation by 43±11% at day 21 ( Figure 1B , open circles, S/AI; P<0.05). Apolipoprotein A-I administration 24 hours before the PG-PS injection, and on days 1, 7, 9, and 11 after the PG-PS injection, reduced joint inflammation by 61±5% at day 3 and by 90±5% at day 21 ( Figure 1C , open circles, AI/AI; P<0.05 for both).
Apolipoprotein A-I Reduces PG-PS-Induced Inflammatory Cell Infiltration and TLR2 Expression in Synovial Tissues
Joint inflammation in arthritis is mediated by the migration of circulating inflammatory cells into synovial tissues, where they subsequently release proinflammatory cytokines. 4 The present results are consistent with these events. When the animals were treated with intravenous saline on day 1 before and days 1, 7, 9, and 11 after inducing arthritis with an intraperitoneal PG-PS infusion, the total white blood cell (WBC), neutrophil, and monocyte counts increased by 6.1±0.5-, 17±1.4-, and 37±4.9-fold, respectively ( Figure 2A -2C, S/S; P<0.05 for all versus animals that received an intraperitoneal saline infusion). CD11b/c, CD44, and combined CD11b/c and CD44 expression on circulating WBCs in the saline-treated animals with PG-PS-induced arthritis also increased by 65±6.0-, 55±1.9-, and 128±7.1-fold, respectively ( Figure 2D -2F, S/S; P<0.05 for all).
When the animals with PG-PS-induced arthritis were treated with apolipoprotein A-I, the WBC, neutrophil, and monocyte counts decreased by 49% to 64% (Figure 2A ), 85% to 92% ( Figure 2B ), and 87% to 93% ( Figure 2C ), respectively (P<0.05 compared with saline-treated animals with arthritis). The number of CD11b/c + ( Figure 2D ), CD44 + ( Figure 2E ), and CD11b/ c + /CD44 + ( Figure 2F ) WBCs in these animals decreased by 75% to 92%, 59% to 90%, and 84% to 97%, respectively (P<0.05 for all versus saline-treated animals with arthritis).
The plasma TNF-α concentration that was below the level of detection in the control animals increased to 3.7±0.8 pg/mL in the saline-treated animals with arthritis ( Figure 2G ). Plasma interleukin (IL)-6 ( Figure 2H ) and IL-1β ( Figure 2I ) levels in the saline-treated animals with PG-PS-induced arthritis increased by 2.7±0.3-and 6.5±0.5-fold, respectively (P<0.05 for all compared with animals without arthritis). When the animals with PG-PS-induced arthritis were treated with apolipoprotein A-I, plasma TNF-α levels decreased by 57% to 64% ( Figure 2G ), IL-6 levels decreased by 42% to 68% ( Figure 2H ), and IL-1β levels decreased by 40% to 55% ( Figure 2I ; P<0.05 for all).
WBCs were not detected in synovial fluid samples from control animals that received a single intraperitoneal injection of saline and were treated with intravenous saline ( Figure 3A -3D, S/S). A single intraperitoneal PG-PS infusion, by contrast, induced massive WBC filtration into the synovial fluid ( Figure 3A and 3B, closed bars). The major synovial fluid WBCs in the PG-PS-treated animals were neutrophils ( Figure 3C ) and monocytes ( Figure 3D ). In the animals with arthritis, treatment with apolipoprotein A-I reduced the WBC count by 47% to 78% ( Figure 3B ), the number of neutrophils by 38% to 72% ( Figure 3C ), and the number of monocytes by 76% to 84% ( Figure 3D ; P<0.05 for all).
Induction of arthritis with PG-PS also increased synovial fluid TNF-α, IL-6, and IL-1β levels by 56±5.0-, 21±1.6-, and 4.5±0.5-fold, respectively ( Figure 3E -3G, closed bars, S/S; P<0.05 for all versus control). Treatment with apolipoprotein A-I reduced the TNF-α ( Figure 3E ), IL-6 ( Figure 3F ), and IL-1β ( Figure 3G ) levels by 65% to 78%, 41% to 61%, and 46% to 65%, respectively, in the animals with arthritis (P<0.05 for all).
Synovial tissue macrophage content (CD68+ cells; Figure 4A ) and TNF-α mRNA levels ( Figure 4B ) increased by 53±6.3-and 3.5±0.3-fold, respectively, in the salinetreated animals with arthritis (S/S, closed bar), relative to the saline-treated control animals (S/S, open bars; P<0.05 for both). Treatment with apolipoprotein A-I reduced the synovial tissue macrophage content by 83% to 90% ( Figure 4A ) and TNF-α mRNA levels by 51% to 67% ( Figure 4B ; P<0.05 for all versus saline-treated animals with arthritis).
Synovial tissue TLR2 mRNA levels were increased 3.2±0.3-fold in the saline-treated animals with PG-PSinduced arthritis ( Figure 4C , closed bar; P<0.05 versus control). Treatment with apolipoprotein A-I reduced TLR2 mRNA levels by 43% to 58% ( Figure 4C ; P<0.05 for all relative to saline-treated animals with arthritis).
Taken together, these results indicate that treatment of female Lewis rats with PG-PS-induced arthritis with apolipoprotein A-I markedly reduces the number of circulating inflammatory cells, that can potentially decrease their migration into synovial tissues and the subsequent release of proinflammatory cytokines. These findings also suggest that the ability of apolipoprotein A-I to reduce joint inflammation in rats with PG-PS-induced arthritis may be related to reduced TLR2 expression in macrophages.
Apolipoprotein A-I Inhibits PG-PS-Induced Inflammation in Macrophages by Attenuating TLR2 Expression and Activation
The inhibition of PG-PS-induced proinflammatory cytokine production by apolipoprotein A-I and the involvement of TLR2 in this process was investigated in HMDMs. Stimulation of HMDMs with PG-PS increased TNF-α ( Figure 5A , closed bar), IL-6 ( Figure 5B , closed bar), and IL-1β ( Figure 5C , closed bar) secretion into the culture medium by 8.5±0.2-, 12±0.9-, and 2.8±0.4-fold, respectively (P<0.05 for all versus control). Preincubation of the HMDMs with apolipoprotein A-I at a final concentration of 0.25, 0.5, and 1.0 mg/mL inhibited the PG-PS-mediated increase in TNF-α levels by 38±5.6%, 53±6.8% and 64±8.1%, respectively ( Figure 5A ), reduced IL-6 levels by 36±10%, 48±12%, and 55±6.9% ( Figure 5B) , and decreased IL-1β levels by 34±9.4%, 53±9.1%, and 60±1.0% ( Figure 5C ; P<0.05 for all).
The ability of apolipoprotein A-I to prevent the PG-PSmediated increase in TLR2 and MyD88 expression and downstream activation of NF-κB in HMDMs was also investigated. Relative to what was observed for control HMDMs (open bars), incubation with PG-PS increased TLR2 ( Figure 5D ) and MyD88 ( Figure 5E Figure 5D ), reduced MyD88 mRNA levels by 32±7.3%, 50±12%, and 62±13% ( Figure 5E ), and decreased nuclear p65 protein levels by 38±2.3%, 50±8.7%, and 69±8.1% ( Figure 5F ; P<0.05 for all). When taken together, these results indicate that apolipoprotein A-I inhibits PG-PSinduced inflammation in macrophages by inhibiting TLR2 and MyD88 gene expression and downstream activation of NF-κB.
To confirm that apolipoprotein A-I inhibited the PG-PSmediated activation of HMDMs in a TLR2-dependent manner, HMDMs were transfected with TLR2 siRNA. TLR2 protein ( Figure IIA 
Apolipoprotein A-I Decreases PG-PS-Induced TLR2 and NF-κB Activation in Macrophages in an ABCA1-Dependent Manner
To investigate the mechanism by which apolipoprotein A-I prevents the PG-PS-induced increase in TLR2 and MyD88 mRNA levels and nuclear translocation of NF-κB, HMDMs were transfected with ABCA1 siRNA, ABCG1 siRNA, SR-B1 siRNA, and scrambled siRNA (siControl) for 24, 48, and 72 hours. ABCA1 protein levels were reduced by 29±18%, 76±9.9% (P<0.05), and 75±13%, respectively, after 24, 48, and 72 hours of transfection with ABCA1 siRNA ( Figure  IIIA Incubation of the scrambled siRNA-transfected HMDMs with PG-PS increased TLR2 mRNA levels 3.3±0.4-fold ( Figure 6A , open bars; P<0.05 relative to control). A similar increase in TLR2 mRNA levels was also observed in HMDMs that were transfected with ABCA1 siRNA, ABCG1 siRNA, and SR-B1 siRNA and incubated with PBS before stimulation with PG-PS ( Figure 6A, closed bars) . This indicates that the PG-PSinduced expression of TLR2 in HMDMs is independent of ABCA1, ABCG1, and SR-B1. Preincubation of the scrambled siRNA-transfected cells with apolipoprotein A-I inhibited the PG-PS-mediated increase in TLR2 mRNA levels by 53±6.9% ( Figure 6A , open bars; P<0.05). TLR2 mRNA levels were similarly inhibited in HMDMs transfected with ABCG1 siRNA and SR-B1 siRNA then preincubated with apolipoprotein A-I before stimulation with PG-PS. Preincubation with apolipoprotein A-I, by contrast, did not inhibit the PG-PS-mediated increase in TLR2 mRNA levels in HMDMs transfected with ABCA1 siRNA (Figure 6A, closed bars) . This indicates that the ability of apolipoprotein A-I to inhibit the PG-PS-mediated increase in TLR2 mRNA levels in HMDMs is dependent on ABCA1 but not on ABCG1 or SR-B1.
To determine whether apolipoprotein A-I also inhibits the PG-PS-mediated increase in HMDM MyD88 mRNA levels, nuclear p65 levels, and TNF-α secretion in an ABCA1-dependent manner, HMDMs were transfected with scrambled siRNA and ABCA1 siRNA. Incubation with PG-PS increased MyD88 levels ( Figure 6B ), nuclear p65 levels ( Figure 6C) , and TNF-α secretion ( Figure 6D Figure 6C , open bars), and TNF-α secretion ( Figure 6D , open bars) by 57±9.4%, 74±14%, and 62±12%, respectively (P<0.05 for all). When the PG-PS-treated HMDMs were transfected with ABCA1 siRNA, apolipoprotein A-I was no longer able to inhibit the PG-PS-induced increase in TLR2 mRNA levels ( Figure 6B , closed bars), nuclear p65 levels ( Figure 6C , closed bars), or TNF-α secretion ( Figure 6D, closed bars) .
rHDLs Inhibit PG-PS-Induced TLR2 Expression and NF-κB Activation in Macrophages and Protect Against PG-PS-Induced Arthritis in Lewis Rats
The ability of CSL-111, an rHDL preparation from CSL Ltd, Australia, to protect against PG-PS-induced arthritis in female Lewis rats was also investigated. The rationale for this experiment was that the longer plasma residence time of CSL-111 relative to that of apolipoprotein A-I may lead to more effective inhibition of joint inflammation, TLR2 expression, and NF-κB activation in HMDMs. 20 Incubation of HMDMs with PG-PS increased TLR2 mRNA ( Figure IVA Figure IVF in the online-only Data Supplement) levels in the culture medium were reduced by 58±1.7%, 51±6.0%, and 73±15%, respectively (P<0.05 for all). Comparison with Figure 5 indicates that CSL-111 inhibits TLR2 expression and downstream NF-κB activation as effectively as apolipoprotein A-I in HMDMs.
The ability of CSL-111 to inhibit the PG-PS-mediated increase in TLR2 mRNA levels in HMDMs was also found to be ABCA1 and ABCG1 but not SR-B1 dependent ( Figure 
Discussion
The ability of apolipoprotein A-I and HDL to inhibit vascular inflammation is well established in vitro 15, 17, 21 and in vivo. 7, 12, 22 This report demonstrates for the first time that apolipoprotein A-I and to a lesser extent the rHDL preparation, CSL-111, also inhibit joint inflammation in female Lewis rats with PG-PS-induced arthritis.
As CSL-111 is likely to be cleared from the circulation less rapidly than lipid-free apolipoprotein A-I, we anticipated that it would be a more effective inhibitor of joint inflammation when compared with apolipoprotein A-I. Comparison of the results in Figure 1 and Figure VI in the online-only Data Supplement indicate that this is not the case. This unexpected result may be a consequence of association with lipid markedly altering the secondary structure of the C-terminal domain of apolipoprotein A-I in CSL-111 23 and decreasing surface exposure of specific apolipoprotein A-I residues or peptide sequences with anti-inflammatory or chemotactic properties.
Given that recruitment of circulating leukocytes is a key event in the pathogenesis of joint inflammation in RA, [24] [25] [26] it is possible that the apolipoprotein A-I-mediated reduction in circulating inflammatory cell levels may have been directly responsible for the decreased number of inflammatory cells and the reduction in proinflammatory cytokine levels in the joints of the PG-PS-treated rats. As HDLs from mice transgenic for human apolipoprotein A-I have recently been shown to suppress myeloid cell proliferation, 27 it is also possible that the reduced number of circulating inflammatory cells in the PG-PS-treated animals may have been caused by an apolipoprotein A-I-mediated decrease in leukocyte production. It is also conceivable that apolipoprotein A-I may have crossed the synovial membrane and inhibited macrophage proinflammatory cytokine production in the joints of the PG-PS-treated animals directly.
The finding that apolipoprotein A-I inhibits PG-PSinduced inflammation in HMDMs by decreasing TLR2 and MyD88 mRNA levels and inhibiting NF-κB activation in an ABCA1-dependent manner convincingly demonstrates that the previously reported anti-inflammatory properties of apolipoprotein A-I and HDLs extend beyond their potential benefit in cardiovascular disease and that they may both have therapeutic applications in other inflammatory pathologies, particularly in humans with RA exacerbations. rHDL infusions and other HDL-raising agents that are currently under investigation in large-scale cardiovascular clinical outcome trials may, therefore, offer an alternative approach for people who do not respond to or cannot tolerate conventional RA therapies, such as TNF inhibitors and the disease-modifying antirheumatic drug, methotrexate. This approach would have the added benefit of reducing cardiovascular risk that is known to be elevated in people with RA. 28 The observations that apolipoprotein A-I inhibits PG-PSinduced inflammatory responses by reducing TLR2 and MyD88 mRNA levels and inhibiting NF-κB activation in macrophages are consistent with earlier reports showing that the anti-inflammatory effects of apolipoprotein A-I and HDLs are related, at least in part, to decreased TLR signaling in a cardiovascular setting. In those studies, incubation of apolipoprotein A-I or HDLs with macrophages 29 and microvascular endothelial cells 30 reduced TLR4 expression and prevented the TLR ligand, lipopolysaccharide, from inducing TLR signaling. The results of the present study confirm that these beneficial effects of apolipoprotein A-I are also apparent in an entirely different pathology. Apolipoprotein A-I and the apolipoprotein A-I mimetic peptide, 4F, have also been reported to decrease TLR4 expression and protect against lipopolysaccharide-induced inflammation in HMDMs. 31 Similarly, the increased HDL levels in mice transgenic for human apolipoprotein A-I are associated with decreased TLR4 expression in the lung and protect against lipopolysaccharide-induced lung inflammation. 30 The current results showing that CSL-111 and apolipoprotein A-I inhibit macrophage and joint inflammation by decreasing TLR expression and signaling, as well as the expression of inflammatory genes in an ABCA1-and ABCG1-dependent manner, are consistent with what was reported for the first time in 2008 by Yvan-Charvet et al, 32 who found that ABCA1-/ABCG1-deficient macrophages with high cholesterol levels had increased TLR4 and MyD88/TRIF expression. HDLs also inhibit NF-κB-dependent responses to TLR ligands 33, 34 in an ABCA1-dependent manner, possibly by decreasing the cholesterol content of lipid rafts and reducing MyD88-dependent TLR trafficking to these domains. 34 This observation is consistent with the finding that the anti-inflammatory effects of HDLs and apolipoprotein A-I are enhanced in cholesterol-depleted macrophages and monocytes. 35, 36 When these findings are considered in light of the current results, which establish that apolipoprotein A-I inhibits PG-PS-induced inflammation in HMDMs in an ABCA1-dependent manner, it follows that the observed reduction in the inflammatory response in the HMDMs in the present study may have been related to a reduction in the cholesterol content of the cells. Although it could be argued that a reduction in cell cholesterol levels cannot explain why CSL-111 inhibited inflammation in HMDMs in an ABCA1dependent manner, it is noteworthy that this result is in agreement with a recent report in which the ability of the closely related formulation, CSL-112, to efflux cholesterol from macrophages was shown to be dependent on ABCA1. 37 Although the possibility of carrying out bone marrow transplantation studies to test this possibility in vivo is appealing, such an approach is unlikely to provide a definitive answer. The confounding issue in experiments of this type is that the infused apolipoprotein A-I and CSL-111 would incorporate rapidly into the endogenous HDL fraction, where they would be remodeled by plasma factors. 38, 39 This would result in the generation of several subpopulations of HDL particles with the capacity to accept cellular cholesterol by multiple pathways.
In conclusion, this study provides mechanistic insights into the potential therapeutic benefit of apolipoprotein A-I and rHDL infusions in arthritis. The results also suggest that HDL-and apolipoprotein A-I-raising agents that are currently being investigated in large-scale cardiovascular clinical outcome trials may be useful in other inflammatory disorders that can be refractory to conventional treatments. 
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